Rare triad of periampullary carcinoid, duodenal gastrointestinal stromal tumor and plexiform neurofibroma at hepatic hilum in neurofibromatosis type 1: a case report

Nihed Abdessayed 1,2, Rahul Gupta 3, Sarra Mestiri 1, Ahlem Bdioui 1, Mounir Trimech 1 and Moncef Mokni 1,2*

Abstract

Background: Neurofibromatosis type 1 is a relatively common inherited disorder. Patients with neurofibromatosis type 1 are at high risk of developing neurogenic, neuroendocrine and mesenchymal intra-abdominal tumors. Although coexistence of multiple tumors of different types is frequent in neurofibromatosis type 1, simultaneous occurrence of abdominal tumors of three types is very rare.

Case presentation: A 66-year-old lady with neurofibromatosis type 1 presented with painless progressive jaundice for six months. Laboratory investigations revealed iron deficiency anemia and conjugated hyperbilirubinemia. Tumor markers were normal. Abdominal computed tomography showed a 3 × 2 cm heterogenous mass in the periampullary region with mild dilation of the common bile duct and another 2 × 1.7 cm mass in the fourth portion of the duodenum. Endoscopic biopsy confirmed the diagnosis of periampullary carcinoid. At surgery, multiple small nodules were detected at the hepatic hilum. Frozen section suggested them to be neurofibromas. Patient underwent pancreatoduodenectomy and had uneventful recovery with no recurrence at two months. Microscopic examination of the resected specimen confirmed presence of three tumors: periampullary well differentiated neuroendocrine tumor, gastrointestinal stromal tumor of the fourth part of duodenum and plexiform neurofibroma at the hepatic hilum.

Conclusion: Patients of neurofibromatosis type 1 with abdominal symptoms should be treated with high index of clinical suspicion and thoroughly evaluated to rule out multiple tumors.

Keywords: Case report, Neurofibromatosis, Neuroendocrine tumor, Gastrointestinal stromal tumor, Neurofibroma, Whipple’s operation

* Correspondence: moncef.mokni@rns.tn; moncefmokni@gmail.com
1 Department of pathology, Farhat Hached Hospital, Avenue Farhat Hached, 4000 Sousse, Tunisia
2 Research Lab. transfer in technology in anatomic pathology (LR12SP08), Sousse, Tunisia
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Neurofibromatosis type 1, also known as von Recklinghausen disease, is an autosomal dominant disorder with an incidence of approximately one in 3000 births [1]. It occurs due to germline mutation of the neurofibromatosis type 1 gene located on chromosome 17 [2]. Neurofibromatosis type 1 gene encodes for a protein acting as a negative regulator of the ras proto-oncogene, which plays an important role in controlling cell growth. However, about 50% of the cases present with new mutations (de novo) without any family history of the disease [3].

Clinically, it is characterized by multiple cutaneous neurofibromas, café-au-lait spots, Lisch nodules (pigmented iris hamartomas) and axillary or inguinal freckling [4]. In addition to central and peripheral nervous system affection, patients with neurofibromatosis type 1 have a higher risk to develop benign or malignant tumors in other parts of the body [3]. Gastrointestinal tract involvement in neurofibromatosis type 1 is less frequent with the reported incidence of 10–25% [5, 6]. On the basis of histologic type, digestive tract neoplasms related to neurofibromatosis type 1 can be divided into five groups [7]: neurogenic neoplasms (neurofibroma, plexiform neurofibroma, ganglioneuroma), neuroendocrine tumors (NET) (carcinoid, pheochromocytoma, paraganglioma), non-neurogenic mesenchymal tumors (gastrointestinal stromal tumor {GIST}, leiomyoma, leiomyosarcoma), embryonal tumors (rhabdomyosarcoma, neuroblastoma, Wilms tumor) and miscellaneous tumors (gastrointestinal adenocarcinoma). Due to variable penetrance, the patient may present with one or more of the above-mentioned tumors in synchronous or metachronous fashion. Although there are several reports of patients with synchronous presentation of abdominal tumors of two types, coexistence of three different tumors is very rare [8].

We report a rare triad of periampullary carcinoid, duodenal GIST and plexiform neurofibroma at hepatic hilum in a lady with neurofibromatosis type 1.

Case presentation

A 66-year-old lady with history of diabetes mellitus was referred for evaluation of painless progressive jaundice for six months associated with fatigue. Physical findings of café-au-lait spots, multiple neurofibromas over the trunk (Fig. 1) along with family history of first degree relative (sister) affected by neurofibromatosis type 1 confirmed the diagnosis of neurofibromatosis type 1 [9, 10]. Generalized icterus was noted however no abdominal lump was palpable. Laboratory analysis showed anemia (hemoglobin - 8.7 g/dl) and deranged liver function tests (total bilirubin – 246 umol/L, conjugated bilirubin – 132 umol/L, AST – 97 U/L, ALT – 70 U/L, GGT – 461 U/L, alkaline phosphatase – 659 U/L). Levels of carcinoembryonic antigen and carbohydrate antigen 19–9 were within normal range. Abdominal computed tomography
showed a $3 \times 2$ cm lesion in the periampullary area of the duodenum showing heterogenous enhancement with mild dilation of the common bile duct and another $2 \times 1.7$ cm lesion in the fourth part of the duodenum (Figs. 1 and 2). Endoscopy showed a bulging mass at the site of major papilla. Biopsy was performed and histologic analysis revealed infiltration of lamina propria and muscularis mucosa with carcinoid cells that were strongly positive for synaptophysin and chromogranin. Urine 5-hydroxyindoleacetic acid levels were within normal limits. The patient underwent pancreateoduodenectomy. Intraoperatively, multiple small nodules were found on the hepatic hilum with the maximum size of approximately 4 cm. Thought to be metastatic lymph nodes, frozen section was performed which revealed spindle cell tumor. The patient had an uneventful postoperative recovery.

The operative specimen (Fig. 3) showed a $3 \times 2 \times 2$ cm non-ulcerated tumor located close to the ampulla of Vater. In addition, firm white-tan submucosal nodule sized 2 cm in greatest diameter was located in the fourth part of duodenum. Microscopically, the later was GIST, consisting of spindle cells arrange in a fascicular pattern without necrosis (Fig. 4). The nuclei were elongated without any significant pleomorphism. The cytoplasm was variably abundant with indistinct cell borders. Mitotic figures were infrequent. Immunohistochemical staining was strongly positive for CD34, CD117 and DOG1 supporting the diagnosis of GIST (Table 1) (Figs. 5 and 6). S100 stain was negative. Histopathological examination of periampullary tumor revealed well-differentiated endocrine tumor Grade 1 with strong immunohistochemical expression of chromogranin, synaptophysin and Ki67 < 1% (Figs. 7, 8 and 9). Also, CK7 and S100 were negative which ruled out adenocarcinoma and paraganglioma respectively. Histologic examination of hepatic hilar nodules showed a spindle cell tumor arranged in fascicular pattern within fibrillar stroma. Nuclei were elongated, thin, without mitotic figures. Tumor cells were positive for S100 and were negative for CD34, CD117 and DOG1 suggestive of plexiform neurofibroma. All the

| Antibody   | Clones | Source    | Dilution |
|------------|--------|-----------|----------|
| Synaptophysin | 27G12  | Novo Castra | 1/100    |
| CD117/c-Kit | Rb     | Dako      | 1/400    |
| Chromogranin A | SH7    | Novo Castra | 1/100    |
| CD34       | QEnd.10| Novo Castra | 1/50     |
| CK7        | OVTL   | Dako      | 1/50     |
| DOG-1      | K9     | Novo Castra | 1/30     |
| S100       | Rb poly| Dako      | 1/400    |
| Ki67       | Mib-1  | Dako      | 1/50     |

Fig. 4 Microscopic appearance of the duodenal gastrointestinal stromal tumor showing skeinoid fibers (H&E $\times$ 200)

Fig. 5 Duodenal GIST showing positive staining with CD117 ($\times$ 100)

Fig. 6 Duodenal GIST showing positive staining with DOG1 ($\times$ 100)
reseption margins were free of tumor. At two months of follow-up after surgery patient was doing well.

**Discussion and conclusions**

Although abdominal tumors are more frequent in neurofibromatosis type 1 than general population, simultaneous existence of three different types of abdominal tumors is extremely rare [8]. To the best of our knowledge, coexistence of periampullary carcinoid, duodenal GIST and plexiform neurofibroma at hepatic hilum has not been described in English literature.

Most of the cases of NET are sporadic but familial forms can be seen as a part of inherited syndromes like multiple endocrine neoplasia type 1 syndrome, tuberous sclerosis or neurofibromatosis [11]. In fact, NETs are reported in about 1% of patients suffering from neurofibromatosis with the most common site being the periampullary region [3]. Histologically, NET comprise a large spectrum that ranges from well differentiated NET grade 1 and 2 to poorly differentiated ones or NE carcinomas and approximately 41% of those occurring in neurofibromatosis type 1 patients were well differentiated. Clinical symptoms are multiple and variable depending on tumor size, compression and spread. The most common presenting symptoms are jaundice (65%) and pain (31%) [11].

Biologically, the most common type of peri-ampullary NET in neurofibromatosis type 1 patients is somatostatinoma (40%) [12]. Diagnosis is made by a combination of radiological imaging, endoscopic ultrasound or endoscopy and measurement of 5-hydroxyindolectic acid and chromogranin [3]. Pancreatocoduodenectomy is the preferred treatment for well-differentiated ampullary carcinoid greater than 2 cm and for ampullary neuroendocrine carcinomas [12]. Local tumor excision can be considered for ampullary carcinoid less than 2 cm [12].

**Table 2** Comparison of characteristics of GIST in NF1 and sporadic cases

| Characteristics                              | GIST in NF1 | Sporadic GIST |
|---------------------------------------------|-------------|---------------|
| Most common location                        | Small bowel | Stomach       |
| Solitary or multiple                        | Multiple    | Solitary      |
| Association with other gastrointestinal tumors like carcinoid | Frequent | Rare |
| KIT or PDGFRA mutations                     | Absent      | Present       |
| Probable molecular pathogenetic mechanism   | Activation of ras-MAP kinase cascade | Gain of function mutation of c-kit proto-oncogene |
| Probable molecular pathogenetic mechanism   | Mitotic recombination | Loss of heterozygosity at 14q and 22q |
| Response to Imatinib mesylate               | Poor        | Good          |
GIST is the most frequent mesenchymal tumors of the gastrointestinal tract in neurofibromatosis type 1 [13, 14]. The incidence in neurofibromatosis type 1 patients is nearly 45-fold higher than that in normal population [14]. The characteristic features of GIST in neurofibromatosis type 1 have been summarized in Table 2. Histologically, majority of tumors have spindle cell morphology with lower mitotic rate and K67 index [4, 14]. Surgery is the only treatment available as they are resistant to imatinib mesylate therapy due to lack of c-kit mutations [5]. The biological behavior is similar to that of GIST in non-neurofibromatosis type 1 patients [7].

Plexiform neurofibroma is a one of the diagnostic features of neurofibromatosis type 1 [7]. They can be present anywhere in the body. Intra-abdominal plexiform neurofibromas are rare with less than 25 cases reported in literature [15]. They are most frequently located in the abdomino-pelvic wall or retroperitoneum [7, 15]. Plexiform neurofibroma involving the liver or peritoneal region comprise 2.3% of all abdominal plexiform neurofibromas [15–17]. Most of these tumors are incidentally detected during abdominal imaging or surgery as seen in our case [15]. In the present case, they were misinterpreted as metastatic lymph nodes. Rarely can they obstruct the main portal vein leading to portal hypertension [15]. These lesions are benign but have the potential to develop into malignant peripheral nerve sheath tumors [7, 15]. Because of the rarity of the disease, optimal timing and extent of surgery is not known. Complete surgical excision is often not feasible due to entrapment of the important vessels within the lesions [15–17].

In conclusion, patients with neurofibromatosis type 1 have high risk of harboring different intra-abdominal tumors simultaneously especially carcinoid and GISTs. High index of clinical suspicion, thorough preoperative and intra-operative evaluation is required to make correct diagnosis and provide appropriate treatment.

Abbreviations
GIST: Gastrointestinal stromal tumor; NET: Neuroendocrine tumor

Acknowledgements
None.

Funding
No specific funding was received for this study.

Availability of data and materials
All the data are included in this published. Additional data can be requested from the department of pathology, Farhat Hached Hospital, Sousse, Tunisia.

Authors’ contributions
NA, SM, RG and AB collected and interpreted the data. NA, SM and RG drafted the manuscript. RG, AB, SM, MT and MM edited the manuscript for important intellectual content. All authors read and approve the final manuscript. All authors take public responsibility for appropriate portions of the content and agree to be accountable for the accuracy of the work.

Ethics approval and consent to participate
This case study was approved by the Ethics Committee of Farhat Hached Hospital, Sousse, Tunisia affiliated to Ministry of Health of Tunisia.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of pathology, Farhat Hached Hospital, Avenue Farhat Hached, 4000 Sousse, Tunisia. Research Lab. transfer in technology in anatomic pathology (LR12SP08), Sousse, Tunisia. 2Department of HPB surgery, CARE hospital, Hyderabad, India.

Received: 9 November 2016 Accepted: 18 August 2017

Published online: 29 August 2017

References
1. Huson SM, Compton DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet. 1989;26:704–11.
2. Xu GF, O’Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62:599–608.
3. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834–43.
4. Bettini P, Falconi M, Cripta S, Capelli P, Boninside L, Pedezzoli P. Ampullary somatostatinomas and jejunal gastrointestinal stromal tumor in a patient with von Recklinghausen’s disease. World J Gastroenterol. 2007;13:2761–3.
5. Pink J, Dukiño O, Ovnat A, Levy I. Gastrointestinal complications of von Recklinghausen’s disease: two case reports and a review of the literature. Scand J Gastroenterol. 2003;38:1275–8.
6. Seymour-Dempsey K, Andressy RJ. Neurofibromatosis: implications for the general surgeon. J Am Coll Surg. 2002;195:553–63.
7. Levy AD, Patel N, Dow N, Abbott RM, Miettinen M, Sobin LH. Abdominal neoplasms in patients with neurofibromatosis type 1: radiologic-pathologic correlation. Radiographics. 2005;25:455–80.
8. James AW, Chang L, Genshaft S, Dry SM. Coincident liposarcoma, carcinoid and gastrointestinal stromal tumor complicating type 1 neurofibromatosis: case report and literature review. J Orthop. 2015;12:511–6.
9. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575–8.
10. Fener RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44:818–21.
11. Teixeira F, Menegozzo CA, CoutoNetto SD, et al. Pancreaticoduodenectomy in patients with type 1 neurofibromatosis: report of two cases and literature review. Int J Surg Case Rep. 2016;27:36–40.
12. Relles D, Baek J, Witkiewicz A, Yeo CJ. Periampullary and duodenal neoplasms in neurofibromatosis type 1: a 20-year review of the literature. Scand J Gastroenterol. 2010;45:1206–15.
13. Agaimy A, Märkl B, Kitz J, et al. Periferal nerve sheath tumors of the gastrointestinal tract: a multicenter study of 58 patients including NF1-associated gastric schwannoma and unusual morphologic variants. Virchows Arch. 2010;456:411–22.
14. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors. 2009;1:e23.
15. Hoshimoto S, Morise Z, Takeura C, et al. Plexiform neurofibroma at the hepatic hilum. Clin Mol Hepatol. 2016;22:276–80.
16. Lee KH, Yoo SH, Noh GT, et al. A case of portal hypertension by presumed as plexiform neurofibroma at the hepatic hilum. Clin Mol Hepatol. 2016;22:1154–7.
17. Fiorini E, Zanoni MR, De Giorgi TJ, et al. Plexiform neurofibroma within the hepatic hilum associated with neurofibromatosis type 1: a case report. Rare tumors. 2009;1:e23.